LAWRENCE, Mass., Oct. 23, 2018 /PRNewswire/ -- NxStage Medical,
Inc. (Nasdaq: NXTM), a leading medical technology company
focused on advancing renal care, today announced a new study
highlighting significant improvements in first-year survival for
incident patients across all age ranges, performing more frequent
home hemodialysis with the NxStage® System
One™.1
The study analyzed United States Renal Data System (USRDS) data
of 557,139 incident dialysis patients who were prescribed more
frequent home hemodialysis (HHD) with the NxStage System One or
conventional in-center hemodialysis (IHD) therapy, shortly after
dialysis initiation. Patients of all ages who initiated more
frequent HHD showed improved survival, having a 23% lower risk of
death versus IHD overall, with the most striking results found in
patients 20-44 years of age, who experienced 44% lower risk of
death.1
These data come on the heels of another study that demonstrated
a steady rise in hospitalization rates among all younger dialysis
patients, in whom three times per week in-center hemodialysis is
most common.2 This increase in hospitalization rates
further supports the need for increased exposure of younger
patients to more frequent home hemodialysis.
"Less than 1% of new dialysis patients each year perform home
hemodialysis, according to the USRDS"3 said Dr.
Eric Weinhandl, NxStage Clinical
Epidemiologist and Biostatistician. "44% lower risk of
death1 is very meaningful, as younger dialysis patients
have indicated that they place higher value on life
expectancy.4 For young adults, maintaining both
cardiovascular health and personal responsibilities and vocations
are important, and increased hemodialysis frequency may be critical
in improving both their clinical and quality of life outcomes."
These findings will be presented at ASN Kidney Week,
October 23-28, 2018, in San Diego, CA, alongside an additional 10
posters and featured oral presentations. The oral sessions are
scheduled for Friday, October 26th at
4:30 and 5:54 PM, in location
2.
Full abstracts can be read online at
https://www.asn-online.org/education/kidneyweek/.
NxStage is also sponsoring an Exhibitor Spotlight Event on
Friday, October 26th at 11:00 AM, Survival After End Stage Renal
Failure: Preventing Cardiac Disease in ESRD Patients, moderated
by Dr. Allan Collins, Chief Medical
Officer of NxStage. This educational program will feature
interactive presentations from experts in both renal and
cardiovascular industries on ultrafiltration rates and their impact
on cardiovascular risk, fluid management and control, and clinical
applications of more frequent hemodialysis.
Conference attendees can meet with NxStage representatives in
booth 1841.
The reported benefits of more frequent home hemodialysis
(HHD) may not be experienced by all patients.
The NxStage System is a prescription device and, like all
medical devices, involves some risks. The risks associated with
hemodialysis treatments in any environment include, but are not
limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
When vascular access is exposed to more frequent use, infection of
the site, and other access related complications may also be
potential risks. The medical devices used in hemodialysis therapies
may add additional risks including air entering the bloodstream,
and blood loss due to clotting or accidental disconnection of the
blood tubing set.
HHD with the NxStage System during waking hours may not
require a care partner, provided a physician and a qualified
patient agree that solo HHD is appropriate. Patients performing
nocturnal treatments are required to have a care partner. Care
partners are trained on proper operation and how to get medical or
technical help if needed.
Certain risks associated with hemodialysis treatment are
increased when performing solo HHD because no one is present to
help the patient respond to health emergencies. Additional
ancillary devices and training are required when performing solo
HHD. Certain risks associated with hemodialysis treatment are
increased when performing nocturnal therapy due to the length of
treatment time and because therapy is performed while the patient
and care partner are sleeping.
Patients should consult their doctor to understand the risks
and responsibilities of performing these therapies using the
NxStage System.
About the NxStage System One
The NxStage System One is
a simple, flexible and portable hemodialysis system that provides a
wide range of dialysis therapy options, including home, more
frequent, solo, and nocturnal dialysis.
Visit www.nxstage.com for more information on therapy
options with the System One.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq:
NXTM) is a leading medical technology company, headquartered in
Lawrence, MA, that develops,
manufactures and markets innovative products for the treatment of
ESRD and acute kidney failure. For more information on NxStage and
its products and services, please visit www.nxstage.com.
Forward-looking Statements
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this release that are not clearly
historical in nature are forward-looking, and the words
"anticipate," "believe," "expect," "estimate," "plan," and similar
expressions are generally intended to identify forward-looking
statements. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors including those that are discussed in
NxStage's filings with the Securities and Exchange Commission,
including its Quarterly Report on Form 10-Q for the quarter ended
June 30, 2018. NxStage is under no
obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Media contact:
Kristen K.
Sheppard, Esq.
ksheppard@nxstage.com
References:
1. Weinhandl ED, Kubisiak K, Ray D,
Collins AJ. Relative survival among incident patients on home
versus in-center hemodialysis. Oral presentation presented at
American Society of Nephrology Kidney Week Conference, 2018.
2. Ray D, Kubisiak K, Collins AJ, Weinhandl ED. Recent trends in
hospital admissions among Medicare dialysis patients. Abstract
presented at American Society of Nephrology Kidney Week Conference,
2018.
3. 2017 USRDS Annual Data Report.
4. Janssen IM, Gerhardus A, von Gersdorff GD, et al. Preferences of
patients undergoing hemodialysis - results from a
questionnaire-based study with 4,518 patients. Patient Prefer
Adherence. 2015;9:847-855.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/new-study-showcases-improved-survival-with-more-frequent-home-hemodialysis-in-incident-dialysis-patients-300735337.html
SOURCE NxStage Medical, Inc.